Success Rates in Biotech - Going The Wrong Way

  • ID: 1094520
  • Report
  • 38 Pages
  • Avance
1 of 3
The report "Success Rates in Biotech - Going The Wrong Way" summarises our review of 211 public biotech companies comprising over 1,500 drug development projects. We have studied the clinical pipelines going back to 2002 based on financial reports and found a striking difference of success probabilities compared to data derived form pharmaceutical companies.

In the report, the success rates resulting from the analysis are discussed, especially in view of their implications to the management of biotech firms and investments in these companies.
Note: Product cover images may vary from those shown
2 of 3
1.1 Why a study on success rates of biotech companies?
1.2 What are success rates?
1.3 The role of success rates
1.4 Are success rates of biotech companies different?

2.1 Origin of Data
2.2 Difference between FDA and EMEA
2.3 Time frame
2.4 Success rates per molecule vs. success rates per indication
2.5 When does a project count as a success?
2.6 Companies of the sample

3.1 Reporting of success and failure
3.2 Distribution of sample over disease groups
3.3 Overall biotech success rates (IND to approval)
3.4 Disease group specific overall success rates (IND to approval)
3.5 Number of projects in different disease groups
3.6 Approvals by EMEA and FDA
3.7 Disease group specific Success Rates
3.7.1 Cancer (481 projects)
3.7.2 Neurology
3.7.3 Infectious (131 projects)
3.7.4 Inflammation (148 projects)
3.7.5 Cardiovascular (76 projects)
3.7.6 Autoimmune (42 projects)
3.7.7 Hematology (30 projects)
3.7.8 Dermatology (27 projects)
3.7.9 Endocrinology (49 projects)
3.7.10 Metabolic (71 projects)
3.7.11 Genitourinary (30 projects)
3.7.12 Musculoskeletal (29 projects)
3.7.13 Gastrointestinal (22 projects)

4.1 Success Rates in Biotech (Avance) and Pharma (Kola, Landis)
4.2 Difference in cancer
4.3 Difference in Neurology
4.4 Difference in Infectious Diseases
4.5 Difference in Inflammation
4.6 Difference in Cardiovascular
4.7 Biotech has more late stage failures
4.8 Case Study: Arpida
4.9 Biotech does not abandon low potential drugs



Figure 1: Spreading of projects on different disease groups
Figure 2: Overall success rates phase 1 to approval (disease group unspecific)
Figure 3: Success rates Phase I to Approval per disease group
Figure 4: Success rates FDA vs EMEA
Figure 5: Success rates in Cancer
Figure 6: Success rates in Neurology
Figure 7: Success rates in Infectious disease
Figure 8: Success rates in Inflammation
Figure 9: Success rates in Cardiovascular
Figure 10: Success rates in Autoimmune
Figure 11: Success rates in Hematology
Figure 12: Success rates in Dermatology
Figure 13: Success rates in Endocrinology
Figure 14: Success rates in Metabolic disease
Figure 15: Success rates in Genitourinary disease
Figure 16: Success rates in Musculoskeletal
Figure 17: Success rate in Gastrointestinal
Figure 18: Overall success rate of all clinical projects over all disease groups
Figure 19: Success rate by phase of development and overall therapeutic areas
Figure 20: Probability to reach market for biotech and Pharma (Kola Landis)
Figure 21: DiMasi Overall disease groups compared to Kola and Avance
Figure 22: Success rates Cancer; Kola – Avance
Figure 23: DiMasi Cancer compared to Kola and Avance
Figure 24: Success rates Neurology; Kola – Avance
Figure 25: Success rates Infectious, Kola – Avance
Figure 26: Success rates Inflammation, Kola – Avance
Figure 27: Success rates Cardiovascular, Kola - Avance


Table 1: List of reviewed biotech companies (publicily traded)
Table 2: Projects in different disease groups and their overall success rates
Table 3: Average clinical R&D spendings for one drug for biotech and Pharma
Table 4: Capitalized costs per commercialized drug
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown